Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of BMS-986172 in Healthy and Obese Participants
NCT04926051Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jun 2021
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BMS-986172 in obesity (4 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Incidence of non-serious Adverse Events up to 35 days, Incidence of Serious Adverse Events up to 35 days and 5 more. Started Jun 2021; status: completed.
02
Drugs
BMS-986172
03
Conditions
obesity
Beyond the preview
Go deeper on NCT04926051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04926051.